Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate

Experimental Eye Research

Volumn 82, Issue 4, 2006, Pages 657-663

  Sakai, Tsutomu ^a   Kohno, Hideo ^a   Ishihara, Tsutomu ^a   Higaki, Megumu ^a   Saito, Saburo ^a   Matsushima, Masato ^a   Mizushima, Yutaka ^a   Kitahara, Kenji ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BP; EAU rats; Nanoparticles; PLA

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; GLIAL FIBRILLARY ACIDIC PROTEIN; NANOPARTICLE; OPSIN; POLYLACTIC ACID; RETINA S ANTIGEN; RHODAMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CHOROID; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA ROD; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; UVEORETINITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; BETAMETHASONE; CHOROID; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; LACTIC ACID; MALE; MICROSCOPY, CONFOCAL; NANOSTRUCTURES; POLYMERS; RATS; RATS, INBRED LEW; RETINA; RETINITIS; RHODAMINES; TREATMENT OUTCOME; UVEITIS;

EID: 31044443626     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2005.09.003     Document Type: Article

References (25)

1. T.L. Bulter, and P.G. Mcmenamin Resident and infiltrating immune cells in the early and late stages of experimental autoimmune uveoretinis Invest. Ophthalmol. Vis. Sci. 37 1996 2195 2210
2. Y. de Kozak, K. Andrieux, H. Villarroya, C. Klein, B. Thillaye-Goldenberg, M.C. Naud, E. Garcia, and P. Couvreur Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis Eur. J. Immunol. 34 2004 3702 3712
3. A.D. Dick, Y.F. Cheng, A. McKinnon, J. Liversidge, and J.V. Forrester Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis, A preliminary report of intranasal induction of tolerance with retinal antigens Br. J. Ophthalmol. 77 1993 171 175
4. M.N.G. Dukes Corticotrophins and corticosteroids M.N.G. Dukes Meyler's Side Effects of Drugs 1996 Elsevier Amsterdam 1189 1209
5. J.V. Forrester, I. Huitinga, L. Lumsden, and C.D. Dijkstra Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats Curr. Eye Res. 17 1998 426 437
6. I. Grizzi, H. Garreau, S. Li, and M. Vert Hydrolytic degradation of devices based on poly (dl-lactic acid) size-dependence Biomaterials 16 1995 305 311
7. M. Higaki, T. Ishihara, N. Izumo, M. Takatsu, and Y. Mizushima Treatment of experimental arthritis with PLGA nanoparticles encapsulating betamethasone sodium phosphate Ann. Rheum. Dis. 64 2005 1132 1136
8. T. Inoki, S. Yamagami, R. Sakai, M. Isobe, T. Tsuru, and H. Kawashima Suppression of experimental autoimmune uveoretinitis by anti-αβ TCR monoclonal antibody Jpn. J. Ophthalmol. 46 2002 518 524
9. T. Ishihara, N. Izumo, M. Higaki, E. Shimada, T. Hagi, L. Mine, Y. Ogawa, and Y. Mizushima Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile J. Controlled Release. 105 2005 68 76
10. G.J. Jaffe, J. Ben-Nun, H. Guo, J.P. Dunn, and P. Ashton Fluocinolone acetonide sustained drug delivery device to treat severe uveitis Ophthalmology 107 2000 2024 2033
11. M. Kodama, J. Numaga, A. Yoshida, T. Kaburaki, T. Oshika, Y. Fujino, G.S. Wu, N.A. Rao, and H. Kawashima Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Greafe's Arch. Clin. Exp. Ophthalmol. 241 2003 927 933
12. T. Niwa, H. Takeuchi, T. Hino, N. Kunou, and Y. Kawashima Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with d,l-lactide/glycolide copolymer (PLGA) by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior J. Controlled. Release. 25 1993 89 98
13. J. Okabe, H. Kimura, N. Kunou, K. Okabe, A. Kato, and Y. Ogura Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate Invest. Ophthalmol. Vis. Sci. 44 2003 740 744
14. H. Okada One-and three-month release injectable microsheres of the LH-RH superagonist leuprorelin acetate Adv. Drug. Deliv. Rev. 28 1997 43 70
15. H. Okada, M. Yamamoto, T. Heya, Y. Inoue, S. Kamei, Y. Ogawa, and H. Toguchi Drug delivery using biodegradable microspheres J. Control. Release. 28 1994 121 129
16. J.M. Parel, P.J. Milne, and R.K. Parrish Recent trends in ocular drug delivery B. Susanne The Macula 2004 Springer New York 261 281
17. F.G. Roberge, R.R. Capsi, and R.B. Nussenblatt Glial retinal Müller cells produce IL-1 activity and have a dual effect on autoimmune T helper lymphocytes. Antigen presentation manifested after removal of suppressive activity J. Immunol. 140 1998 2193 2196
18. Y. Sasamoto, S. Ohno, and H. Matsuda Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease Ophthalmologica 201 1990 162 167
19. S.P. Schwendeman Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems Crit. Rev. Ther. Drug. Carrier Syst. 19 2002 73 98
20. S.R. Thurau, C.C. Chan, R.B. Nussenblatt, and R.R. Caspi Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals Clin. Exp. Immunol. 109 1997 370 376
21. E. Toker, H. Kazokoglu, and N. Acar High dose intravenous steroid therapy for severe posterior segment uveitis in Behcet's disease Br. J. Ophthalmol. 86 2002 521 523
22. C. Verwaerde, M.C. Naud, A. Delanoye, M. Wood, B. Thillaye-Goldenberg, C. Auriault, and Y. de Kozak Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis Gene. Ther. 10 2003 1970 1981
23. D. Wakefield, P. McCluskey, and R. Penny Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease Arch. Ophthalmol. 104 1986 847 851
24. D. Wakefield, A. Jennings, and P.J. McCluskey Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis Clin. Exp. Ophthalmol. 28 2000 103 106
25. G. Zhu, S.R. Mallery, and S.P. Schwendeman Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide) Nat. Biotechnol. 18 2000 52 57